Handelsavisen
prelaunch
Companies Healthcare CC5.AX
CC
CC5.AX ASX Biotechnology & Medical Research

Clever Culture Systems Ltd

A$0,02
Open in Charts → Attach watcher ⌖
AUD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
ROE
Net margin
Debt / equity
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Clever Culture Systems Ltd has a fully diluted share count of 2,177,122,833, with no difference between basic and diluted shares outstanding, indicating no immediate dilution risk from stock options or convertible securities. However, the company's liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. The company's profitability and return metrics are not available in the valuation snapshot, making it difficult to assess its performance against industry_config preferred metrics or cohort medians. Without these metrics, a direct comparison to industry benchmarks is not feasible. Clever Culture Systems Ltd's revenue concentration by segment and geography is not disclosed in the available data, limiting the ability to evaluate its exposure to specific markets or product lines. This lack of transparency may affect the assessment of its diversification and resilience to regional or segment-specific risks. The company's growth trajectory is not quantified in the outlook, as no numeric deltas or revenue history are provided. This absence of forward-looking guidance and historical performance data hinders the a

Business. Clever Culture Systems Ltd (CC5.AX) is a biotechnology and medical research company focused on healthcare diagnostics. The firm is listed on the Australian Securities Exchange. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
not yet wired
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning CC5.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to CC5.AX. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Clever Culture Systems Ltd (CC5.AX) is a biotechnology and medical research company focused on healthcare diagnostics. The firm is listed on the Australian Securities Exchange. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityHealthcare Diagnostics
    AI synthesis
    GENERATED

    Clever Culture Systems Ltd has a fully diluted share count of 2,177,122,833, with no difference between basic and diluted shares outstanding, indicating no immediate dilution risk from stock options or convertible securities. However, the company's liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.

    The company's profitability and return metrics are not available in the valuation snapshot, making it difficult to assess its performance against industry_config preferred metrics or cohort medians. Without these metrics, a direct comparison to industry benchmarks is not feasible.

    Clever Culture Systems Ltd's revenue concentration by segment and geography is not disclosed in the available data, limiting the ability to evaluate its exposure to specific markets or product lines. This lack of transparency may affect the assessment of its diversification and resilience to regional or segment-specific risks.

    The company's growth trajectory is not quantified in the outlook, as no numeric deltas or revenue history are provided. This absence of forward-looking guidance and historical performance data hinders the ability to project future growth or assess the company's momentum.

    The risk assessment indicates a low dilution risk, but the liquidity risk remains unknown. The absence of balance-sheet data and going-concern language in source documents prevents a more detailed evaluation of the company's financial stability and access to capital.

    Recent events, such as filings or transcripts, are not disclosed in the available data, limiting the ability to assess the company's strategic direction or operational developments. This lack of recent information may affect the understanding of the company's current position and future prospects.

    Key takeaways
    • Clever Culture Systems Ltd has no immediate dilution risk, as basic and diluted shares are equal.
    • The company's liquidity risk could not be assessed due to missing balance-sheet data and no going-concern language.
    • Profitability and return metrics are not available, preventing a comparison to industry benchmarks.
    • Revenue concentration by segment and geography is not disclosed, limiting the understanding of diversification.
    • Growth trajectory and historical performance data are not provided, making future projections difficult.
    • Recent events or strategic developments are not disclosed in the available data.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Annual
    ANNUALFiled 2023-08-31
    FY 2023 · Full-year highlights

    Revenue A$2.1M, −5,3% YoY; Operating income −186,9% YoY.

    RevenueA$2.1M−5,3 % YoY
    Operating income-A$20.5M−186,9 % YoY
    Net income-A$22.5M−239,2 % YoY
    Free cash flow-A$19.5M−349,8 % YoY
    EPS
    Operating cash flow-A$1.4M+71,8 % YoY
    Financials
    Income statement
    RevenueA$2.1M
    Gross profitA$1.7M
    Operating income-A$20.5M
    Net income-A$22.5M
    Margins
    Gross margin80.2%
    Operating margin-953.2%
    Net margin-1048.1%
    FCF margin-908.9%
    Balance sheet
    Total assetsA$7.4M
    Total liabilitiesA$7.5M
    Total equity-A$105.0k
    Cash & equivalentsA$160.0k
    Long-term debtA$2.4M
    Cash flow
    Operating cash flow-A$1.4M
    CapEx-A$305.0k
    Free cash flow-A$19.5M
    SBC
    P&L flow · revenue → net income
    Revenue A$2.1MOperating costs A$22.6MTax A$2.0MNet income A$22.5M
    Highlights
    • Revenue A$2.1M, −5,3% YoY
    • Operating income −186,9% YoY
    • Net income −239,2% YoY
    • Free cash flow −349,8% YoY
    • Net margin -1048.1%

    Valuation FY

    Market price
    A$0,02
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    Net cash
    Current ratio
    Debt / equity
    ROA
    ROE
    Cash conversion
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskUnknown

    Benchmarks vs cohort

    No cohort benchmark data available for this issuer yet.

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    Source documents
    • Clever Culture Systems Ltd Market data — financials · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    CC5.AXCanonical
    ASX · AUD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskUnknown

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2023-08-31 03:39 UTCEARNINGSAnnual results — FY 2023 Revenue AUD 2.1M · Net AUD -22.5M
    2022-08-29 06:33 UTCEARNINGSAnnual results — FY 2022 Revenue AUD 2.3M · Net AUD -6.6M
    2021-08-26 08:07 UTCEARNINGSAnnual results — FY 2021 Revenue AUD 1.4M · Net AUD -7.3M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage